Anxiety

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Case reports have shown a potential association with adverse psychological effects.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The CBT-based intervention, compared with routine pregnancy care, demonstrated reductions of 81% and 74% for depression and anxiety, respectively.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

One significant difference was an increased rate of bupropion prescriptions for transgender females.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

As the body of data has grown, clinicians’ propensity to use selective serotonin reuptake inhibitors off-label has increased

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

Modern society has put individuals at an increased risk of dopamine overload, causing an increase in mental health disorders.

Person-centered care focuses on tailoring treatment plans, providing medication support, and ensuring access to resources that meet their unique needs.

Latinx teens suffering with mental health issues are at risk of developing cardiovascular conditions in their future.

Mental health treatment may be necessary when SAEs occur.

Adolescents with mental health conditions must be monitored as they are at a higher demand for the need of mental health care.

Patients under the care of psychiatric facilities, particularly those taking antipsychotic and antidepressant medications, face the risk of prolonged QTc intervals.

The use of psilocybin, repeated at a low dose, could offer a new form of treatment for individuals with differing forms of mental disorders.

Ketamine topical cream may alleviate symptoms of PTSD without causing the adverse effects and abuse potential often associated with other forms of ketamine administration.

An overview of antidepressant medications and their indications to inform health care professionals of their wide use and to better understand which antidepressant to recommend based on patient-specific characteristics.

Study results could lead to an FDA approval for MDMA to treat post-traumatic stress disorder by the end of 2023.

Although findings indicate a relationship between vitamin D and mood disorders, further research is needed to clarify efficacy of specific vitamin D levels, as well as supplement dose and form.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.

Further research and regulatory changes are needed, but psychedelic medicines may be able to treat or even cure mental illness in the future.

The benefits of the survey can stretch beyond assessing the parental acceptability of mental health screenings in children and can suggest areas of optimization in providing these screenings more widely and effectively in the future.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Pharmacogenomic testing in combination with therapeutic drug monitoring can be a cost effective and efficient way to advance psychiatric drug therapy.

Anxiety disorders create social and economic burdens as the availability of effective anxiolytic treatments are low.